Literature DB >> 16871231

Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.

S Yamamoto1, L A Deckter, K Kasai, E A Chiocca, Y Saeki.   

Abstract

An increasing number of oncolytic viruses have been developed and studied for cancer therapy. In response to needs for non-invasive monitoring and imaging of oncolytic virotherapy, several different approaches, including a positron emission tomography-based method, a method using secreted marker peptides, and optical imaging-based methods, have been reported. Among these modalities, we utilized the luciferase-based bioluminescent assay/imaging systems to determine the kinetics and dynamics of a productive viral infection. The replication cycle of herpes simplex virus type 1 (HSV-1) is punctuated by a temporal cascade of three classes of viral genes: immediate-early (IE), early (E) and late (L) genes. U(L)39- and gamma(1)34.5-deleted, replication-conditional HSV-1 mutants that express firefly luciferase under the control of the IE4/5 or strict-late gC promoters were generated. These oncolytic viruses were examined in cultured cells and a mouse tumor model. IE promoter- and strict-late promoter-mediated luciferase expression was confirmed to indicate viral infection and replication, respectively. Incorporation of a strict-late promoter-driven luciferase cassette into oncolytic HSV-1 vectors would be useful for assessing tumor oncolysis in preclinical tumor treatment studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871231     DOI: 10.1038/sj.gt.3302831

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  12 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

2.  Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.

Authors:  Hiroshi Nakashima; Tran Nguyen; Kazue Kasai; Carmela Passaro; Hirotaka Ito; William F Goins; Imran Shaikh; Ronald Erdelyi; Reiko Nishihara; Ichiro Nakano; David A Reardon; Ana C Anderson; Vijay Kuchroo; E Antonio Chiocca
Journal:  Clin Cancer Res       Date:  2018-03-06       Impact factor: 12.531

3.  Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.

Authors:  Fernando Diaz; Sean Gregory; Hiroshi Nakashima; Mariano S Viapiano; David M Knipe
Journal:  Virology       Date:  2017-10-22       Impact factor: 3.616

4.  NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.

Authors:  Yoshihiro Otani; Ji Young Yoo; Cole T Lewis; Samantha Chao; Jessica Swanner; Toshihiko Shimizu; Jin Muk Kang; Sara A Murphy; Kimberly Rivera-Caraballo; Bangxing Hong; Joseph C Glorioso; Hiroshi Nakashima; Sean E Lawler; Yeshavanth Banasavadi-Siddegowda; John D Heiss; Yuanqing Yan; Guangsheng Pei; Michael A Caligiuri; Zhongming Zhao; E Antonio Chiocca; Jianhua Yu; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

5.  VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.

Authors:  Todd R Wuest; Daniel J J Carr
Journal:  J Exp Med       Date:  2009-12-21       Impact factor: 14.307

6.  "Armed" oncolytic herpes simplex viruses for brain tumor therapy.

Authors:  Tomoki Todo
Journal:  Cell Adh Migr       Date:  2008-07-28       Impact factor: 3.405

7.  Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Authors:  Kaoru Tamura; Hiroaki Wakimoto; Aayush S Agarwal; Samuel D Rabkin; Deepak Bhere; Robert L Martuza; Toshihiko Kuroda; Randa Kasmieh; Khalid Shah
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

8.  Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.

Authors:  Darshini Kuruppu; Anna-Liisa Brownell; Khalid Shah; Umar Mahmood; Kenneth K Tanabe
Journal:  Cancer Res       Date:  2014-05-29       Impact factor: 12.701

9.  Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.

Authors:  P Grandi; J Fernandez; O Szentirmai; R Carter; D Gianni; M Sena-Esteves; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2010-05-28       Impact factor: 5.987

10.  Theranostic potential of oncolytic vaccinia virus.

Authors:  Juan J Rojas; Steve H Thorne
Journal:  Theranostics       Date:  2012-04-05       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.